

To: [REDACTED] [REDACTED] [REDACTED]@rivm.nl
From: [REDACTED] [REDACTED]
Sent: Tue 1/26/2021 1:19:16 PM
Subject: FW: NIH R21 Grant application on Seroprevalence of human coronaviruses and other viruses
Received: Tue 1/26/2021 1:19:17 PM
[SPECIFIC AIMS FINAL.docx](#)
[Research Plan1_tge.docx](#)

Hoi,

Doe je ook mee? Ik heb beloofd deze week feedback te geven *
Heb jij al een NIH CV?

Gr [REDACTED]

From: [REDACTED] [REDACTED] <[REDACTED]@gmail.com>
Sent: dinsdag 26 januari 2021 14:17
To: [REDACTED] [REDACTED] <[REDACTED]@rivm.nl>
Subject: NIH R21 Grant application on Seroprevalence of human coronaviruses and other viruses

Dear [REDACTED]

I have been busy working on the grant application. It is due midFeb 2020 but I plan to submit by the 12th February. I know that you are very busy but please find attached the Specific Aims (I sent an earlier draft), and Research Plan written in the NIH format.. I will need several things from you including:

1. Letter of Support--I can send you a draft letter
2. Your NIH Biosketch if you have but I can convert your CV into the biosketch format
3. A description of your Facilities and Resources which are available for the project--can send the format or example
4. A description of the Equipment that will be used.--can send format or example
5. Budget

I will be happy to incorporate your suggestions for example the influenza viruses and arboviruses to be included into the protein microarray. Regarding arboviruses, Uganda has had several epidemic outbreaks of Yellow Fever, Rift Valley Fever, and Crimean-Congo Hemorrhagic Fever. This study could therefore inform national preparedness and response to future epidemics,

I look forward to hearing from you soon.

Best regards

[REDACTED]

I